Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TCRT
stocks logo

TCRT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q2
0.00
-100%
--
--
Estimates Revision
Stock Price
Go Up
up Image
+66.20%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Alaunos Therapeutics Inc (TCRT.O) is -0.17, compared to its 5-year average forward P/E of -3.61. For a more detailed relative valuation and DCF analysis to assess Alaunos Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.61
Current PE
-0.17
Overvalued PE
-0.74
Undervalued PE
-6.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.56
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.63
Undervalued EV/EBITDA
-2.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3367.17
Current PS
0.00
Overvalued PS
13016.80
Undervalued PS
-6282.46
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TCRT News & Events

Events Timeline

(ET)
2025-06-23
08:05:06
Alaunos prices 610,399 shares at $3.36 in registered direct offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
09-03Benzinga
4 Biotech Stocks Experiencing Decline: Momentum Scores Diminishing in the Last Week

  • Biotech Stocks Momentum Decline: Several biotech stocks have experienced significant declines in their Momentum scores over the past week, indicating a loss of strength in the sector.

  • Key Companies Affected: Notable companies like Capricor Therapeutics, Lava Therapeutics, Alaunos Therapeutics, and Champions Oncology have all reported drops in their Momentum scores due to various factors, including regulatory setbacks, financial losses, and downgrades from analysts.

[object Object]
Preview
8.5
06-18Globenewswire
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

  • PMGC Capital's Urging of Alaunos Therapeutics: PMGC Capital LLC has publicly urged Alaunos Therapeutics to accept a financing term sheet facilitated by a leading Wall Street bank, emphasizing that it represents a significant opportunity for the company and its shareholders.

  • Commitment to Shareholder Value: PMGC Capital remains dedicated to collaborating with Alaunos' leadership to enhance long-term shareholder value while commending the company's prudent financial management during challenging market conditions.

[object Object]
Preview
8.5
05-14Newsfilter
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

  • PMGC Capital's Acquisition: PMGC Capital LLC announced its acquisition of 83,500 shares (approximately 5.09%) in Alaunos Therapeutics, indicating a belief that the company is undervalued and has potential for growth.

  • Strategic Engagement Plans: PMGC Capital intends to engage with Alaunos' management to explore strategic opportunities such as mergers, acquisitions, or partnerships, while commending Alaunos for its financial stewardship.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alaunos Therapeutics Inc (TCRT) stock price today?

The current price of TCRT is 3.59 USD — it has increased 0.84 % in the last trading day.

arrow icon

What is Alaunos Therapeutics Inc (TCRT)'s business?

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

arrow icon

What is the price predicton of TCRT Stock?

Wall Street analysts forecast TCRT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRT is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alaunos Therapeutics Inc (TCRT)'s revenue for the last quarter?

Alaunos Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Alaunos Therapeutics Inc (TCRT)'s earnings per share (EPS) for the last quarter?

Alaunos Therapeutics Inc. EPS for the last quarter amounts to -0.53 USD, decreased -24.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alaunos Therapeutics Inc (TCRT)'s fundamentals?

The market is revising No Change the revenue expectations for TCRT for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 66.20%.
arrow icon

How many employees does Alaunos Therapeutics Inc (TCRT). have?

Alaunos Therapeutics Inc (TCRT) has 1 emplpoyees as of December 05 2025.

arrow icon

What is Alaunos Therapeutics Inc (TCRT) market cap?

Today TCRT has the market capitalization of 8.01M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free